Throughout the last ten years, Eximmium’s scientists have established, and constantly improved, a proprietary workplan for the discovery of new target molecules on cancer cells and the simultaneous generation of corresponding high-quality antibodies. This technology utilizes patient-derived material and extracellular vesicles, which are constantly released at high numbers by cancer cells and which represent the relevant parts of these cells perfectly.
Developing first-in-class antibodies against solid tumors
Revolutionizing cancer therapy with new targets and superior antibodies
With its proprietary platform technology, Eximmium has identified a series of completely new targets on cancer cells and established a large collection of proprietary first-in-class antibodies.